Kolexia
Valteau-Couanet Dominique Pédiatrie
Valteau-Couanet Dominique
Pédiatrie
Gustave-Roussy
Villejuif, France
318 Activités
262 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Neuroblastome Tumeurs du cerveau Médulloblastome Récidive tumorale locale Tumeurs osseuses Gliome Tumeurs du cervelet Maladie résiduelle Sarcome d'Ewing

Collaborateurs

Voir plus
Dufour Christelle
Dufour Christelle
Gustave-Roussy, Villejuif, France
Schleiermacher Gudrun
Schleiermacher Gudrun
Clcc Institut Curie, Paris, France
Grill Jacques
Grill Jacques
Gustave-Roussy, Villejuif, France
Michon Jean
Michon Jean
Clcc Institut Curie, Paris, France

Industries

Voir plus
Norgine
4 collaboration(s)
Dernière en 2022
EXAFIELD
1 collaboration(s)
Dernière en 2023
Eusa Pharma
1 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
European journal of cancer (Oxford, England : 1990)   15 février 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   08 janvier 2024
Thoracoscopy for Pediatric Thoracic Neurogenic Tumors-A European Multi-Center Study.
Cancers   18 novembre 2023
HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE
Abstracts from the 55th Congress of the International Society of Paediatric Oncology (SIOP) October 11–14, 2023   02 novembre 2023
RISK FACTORS IN HIGH RISK NEUROBLASTOMA PATIENTS OVER 5 YEARS: RESULTS FROM THE HR-NBL1/SIOPEN TRIAL
Abstracts from the 55th Congress of the International Society of Paediatric Oncology (SIOP) October 11–14, 2023   02 novembre 2023
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?
British journal of cancer   21 août 2023
Phase II study of I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.
Pediatric blood & cancer   13 août 2023
Predictive factors of long-term follow-up attendance in very long-term childhood cancer survivors.
Cancer   11 juillet 2023
BEACON: A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Essai Clinique (Eusa Pharma)   09 mai 2023
La Consult' de Dominique Valteau-Couanet : "Les clowns sont attendus à ...
What'up doc le Mag   23 mars 2023